Researchers Improve CAR T-Cell Therapy for HIV

3D illustration of a red coronavirus particle surrounded by smaller virus particles on a dark background
Image description: T cell infected with HIV.
Image Credit: National Institute of Allergy and Infectious Diseases (NIAID)

Despite major advances in treatment, HIV remains a global health challenge.

Current medications can control the virus, but they do not eliminate it. People living with HIV typically require lifelong treatment to keep the virus in check.

Researchers continue to search for new approaches that could provide long-term protection and, ultimately, a functional cure.

One promising strategy comes from Dr. Scott Kitchen and his team at UCLA, who are developing a CAR-T cell therapy designed to help the immune system fight HIV.

Engineering Immune Cells to Fight HIV

HIV attacks T cells, a critical component of the immune system.

As the virus destroys these cells, the body becomes less able to fight infections and disease.

To counter that process, Dr. Kitchen’s team uses a form of immunotherapy known as chimeric antigen receptor (CAR) T-cell therapy.

The approach starts with blood-forming stem cells. Researchers genetically modify those cells so they can produce T cells that recognize and attack HIV-infected cells.

The goal is to create a self-renewing source of HIV-fighting immune cells.

Unlike conventional treatments, the therapy may also generate long-lived memory cells that continue to recognize HIV over time.

Building Longer-Lasting Protection

Earlier versions of the therapy produced new HIV-targeting T cells that persisted for more than two years.

However, the original design had an important limitation.

While the engineered cells could fight HIV, they still remained vulnerable to infection by the virus.

Researchers wanted to solve that problem.

In a CIRM-funded study published in PLOS Pathogens, the team redesigned the CAR-T therapy to make the engineered cells resistant to HIV infection.

The updated approach not only protects the therapeutic cells but also improves their ability to mount a stronger and more durable immune response.

Training the Immune System to Respond Faster

The redesigned therapy changes how the immune system responds to HIV.

In previous versions, the engineered T cells remained largely inactive until they encountered the virus.

The new strategy prepares the immune system in advance.

The concept resembles vaccination. Rather than waiting for HIV to trigger a response, the therapy primes immune cells to recognize and respond more rapidly.

The researchers also observed the formation of larger numbers of memory T cells.

These specialized cells can detect and respond quickly if dormant HIV becomes active again.

That capability could prove especially important because HIV can remain hidden in the body and reactivate later.

Moving Closer to a Functional Cure

The findings suggest that engineered stem cells may help create a durable population of HIV-resistant immune cells.

Researchers hope this approach will eventually provide long-lasting control of the virus without the need for continuous treatment.

The work could also have implications beyond HIV.

Scientists are increasingly interested in developing immune cells that carry lasting “memory” and can recognize disease-causing targets over time.

Similar strategies could help treat certain cancers and other chronic diseases.

Looking Ahead

While the research remains in the preclinical stage, the results represent an important step forward in the development of cell and gene therapies for HIV.

By creating HIV-resistant immune cells with long-term memory, researchers hope to build a stronger and more durable immune defense against the virus.

CIRM has supported a broad portfolio of HIV research and has invested more than $31 million in four clinical trials focused on HIV/AIDS therapies.

These efforts reflect the continued search for treatments that move beyond disease management and toward lasting control or elimination of HIV.

2 thoughts on “Researchers Improve CAR T-Cell Therapy for HIV”

Leave a Reply